3-antigen Staphylococcus aureus vaccine - Pfizer

Drug Profile

3-antigen Staphylococcus aureus vaccine - Pfizer

Alternative Names: 3-antigen Staphylococcus aureus vaccine - Inhibitex/Pfizer; PF-05230894; PF-5230894; SA3Ag; Staph vaccine - Inhibitex/Pfizer; Staphylcoccus aureus vaccine - Inhibitex/Pfizer; Staphylococcus aureus vaccine (3-antigen) - Pfizer; WYE-400062

Latest Information Update: 14 Nov 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 10 Nov 2011 Discontinued - Phase-I for Staphylococcal infections in Australia (IM)
  • 08 Aug 2011 Phase-I/II clinical trials in Staphylococcal infections in USA (IM)
  • 31 Jul 2011 Pfizer completes a phase I trial in healthy volunteers in Australia (NCT01018641)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top